HCV Treatment
CROI 2016: Ravidasvir Plus Sofosbuvir Demonstrates High Cure Rate for HCV Genotype 4
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 04 March 2016 00:00
- Written by Liz Highleyman
Sofosbuvir plus the investigational HCV NS5A inhibitor ravidasvir, with or without ribavirin, cured 95% to 100% of people with hepatitis C virus (HCV) genotype 4, the most common type in Egypt, according to findings from the Pyramid 1 study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last week in Boston.
Coverage of the 2016 Conference on Retroviruses and Opportunistic Infections
- Details
- Category: HIV Treatment
- Published on Friday, 26 February 2016 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2016 Conference on Retroviruses and Opportunistic infections (CROI 2016), February 22-25, 2016, in Boston.
HIVandHepatitis.com coverage by topic
2/26/16
FDA Approves Harvoni for Hepatitis C Patients with Advanced Liver Disease
- Details
- Category: Approved HCV Drugs
- Published on Wednesday, 17 February 2016 00:00
- Written by Gilead Sciences
The U.S. Food and Drug Administration (FDA) has approved an expanded indication for Gilead Sciences sofosbuvir/ledipasvir coformulation (Harvoni) plus ribavirin for genotype 1 chronic hepatitis patients with decompenated liver cirrhosis and for genotype 1 or 4 liver transplant recipients without cirrhosis or with compensated cirrhosis, the company announced this week.
Daclatasvir Plus Asunaprevir Cures Most Genotype 1b Chinese Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 23 February 2016 00:00
- Written by Bristol-Myers Squibb
An interferon- and ribavirin-free dual combination of Bristol-Myers Squibb's hepatitis C virus (HCV) NS5A inhibitor daclatasvir (Daklinza) and HCV protease inhibitor asunaprevir (Sunvepra) produced sustained response in more than 90% of genotype 1b chronic hepatitis C patients in China, researchers reported at the 25th Conference or the Asian Pacific Association for the Study of the Liver this week in Tokyo.
FDA Approves Daclatasvir + Sofosbuvir for Hard-to-Treat Hepatitis C Patients
- Details
- Category: Approved HCV Drugs
- Published on Friday, 12 February 2016 00:00
- Written by Bristol-Myers Squibb
The U.S. Food and Drug Administration (FDA) this month approved an expanded indication for Bristol-Myers Squibb's daclatasvir (Daklinza) and Gilead Sciences sofosbuvir (Sovaldi) for additional patient groups including people with HIV/HCV coinfection, patients with advanced liver cirrhosis, and liver transplant recipients.
More Articles...
- AASLD 2015: MiR-122 Inhibitor RG-101 Suppresses Hepatitis C Virus with Single Dose
- FDA Approves Zepatier (Grazoprevir/Elbasvir) for Hepatitis C Genotypes 1 and 4
- AbbVie Opens Global Phase 3 Studies of ABT-493/ABT-530 Hepatitis C Regimen
- AASLD 2015: 3-Drug Combos for 8 Weeks Demonstrate High Hepatitis C Cure Rate
Web Design and Development by